Treatment of adipocytes with agonists TUG-891 (selective for the FFAR4) and GW9508 (selective for FFAR1/GPR40) induce deoxyglucose uptake [84,85], thus indicating a promising role to counteract obesity and insulin resistance. Here, FFAR1 is linked to obesity disorder.